Last reviewed · How we verify
Detox-B adjuvant — Competitive Intelligence Brief
phase 3
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Detox-B adjuvant (Detox-B adjuvant) — GlaxoSmithKline. Detox-B adjuvant enhances immune response by promoting detoxification pathways and supporting innate immunity.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Detox-B adjuvant TARGET | Detox-B adjuvant | GlaxoSmithKline | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Detox-B adjuvant CI watch — RSS
- Detox-B adjuvant CI watch — Atom
- Detox-B adjuvant CI watch — JSON
- Detox-B adjuvant alone — RSS
Cite this brief
Drug Landscape (2026). Detox-B adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/detox-b-adjuvant. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing